Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Amortization of Deferred Charges (2017 - 2023)

Historic Amortization of Deferred Charges for Standard Biotools (LAB) over the last 7 years, with Q4 2023 value amounting to $173000.0.

  • Standard Biotools' Amortization of Deferred Charges fell 1435.64% to $173000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $770000.0, marking a year-over-year decrease of 722.89%. This contributed to the annual value of $770000.0 for FY2023, which is 722.89% down from last year.
  • Standard Biotools' Amortization of Deferred Charges amounted to $173000.0 in Q4 2023, which was down 1435.64% from $187000.0 recorded in Q3 2023.
  • In the past 5 years, Standard Biotools' Amortization of Deferred Charges registered a high of $2.0 million during Q1 2019, and its lowest value of -$194000.0 during Q4 2019.
  • Its 5-year average for Amortization of Deferred Charges is $247631.6, with a median of $187000.0 in 2023.
  • Within the past 5 years, the most significant YoY rise in Standard Biotools' Amortization of Deferred Charges was 30336.63% (2019), while the steepest drop was 10728.23% (2019).
  • Quarter analysis of 5 years shows Standard Biotools' Amortization of Deferred Charges stood at -$194000.0 in 2019, then skyrocketed by 167.01% to $130000.0 in 2020, then soared by 51.54% to $197000.0 in 2021, then rose by 2.54% to $202000.0 in 2022, then dropped by 14.36% to $173000.0 in 2023.
  • Its Amortization of Deferred Charges stands at $173000.0 for Q4 2023, versus $187000.0 for Q3 2023 and $206000.0 for Q2 2023.